FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379983886> ?p ?o ?g. }

• W4379983886 endingPage "1003" @default.
• W4379983886 startingPage "1003" @default.
• W4379983886 abstract "Abstract Background: Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) has an oncogenic role in pancreatic ductal adenocarcinoma (PDAC). Since high expression of P4HA1 in PDAC is suggested to correlate with poor prognosis, targeting P4HA1 could have therapeutic benefits. Herein, we assessed the prognostic significance of P4HA1 expression at the RNA and protein levels in PDAC using publicly available data. We also evaluated the efficacy of diethyl-pythiDC, a small molecule inhibitor of P4HA1, in PDAC cells. Methods: UALCAN (ualcan.path.uab.edu), a comprehensive proteogenomic cancer data analysis portal, was used to obtain gene expression P4HA1 as transcripts per million reads (TPM) (PDAC n=178) from The Cancer Genome Atlas (TCGA); levels of P4HA1 protein expression data were obtained from (normal pancreas, n=74, PDAC n=137) the Clinical Proteomic Tumor Analysis consortium (CPTAC). Immunohistochemical analysis obtained from Human Protein Atlas (HPA) confirmed increased P4HA1 protein expression. Overall survival (OS) between patients with high and low/medium TPM (TPM values above and below upper quartile, respectively) and high and low protein expression score (based on staining intensity and fraction of stained cells) was calculated using the log-rank Wilcoxon test. To determine the efficacy of diethyl-pythiDC in PDAC cells (PANC-1 and BxPC-3), we performed clonogenic assay for colony formation, MTT assay for cell proliferation, flow cytometry for cell cycle analysis, and western blotting for markers of the epithelial-mesenchymal transition (EMT). Results: In the TCGA data, high P4HA1 expression (TPMs) was associated with a poor prognosis (high expression vs. low/medium expression, log-rank p=0.009). Analysis of HPA data showed that the 5-year OS of patients with high P4HA1 expression was 12% vs. 58% for patients with low P4HA1 (log-rank p&lt;0.001). CPTAC data showed higher P4HA1 protein expression in patients with receptor tyrosine kinase (RTK) pathway (p&lt;0.001), mammalian target of rapamycin (mTOR) pathway (p=0.045) and SWItch/Sucrose Non-Fermentable (SWI-SNF) complex (p=0.022) alterations. Diethyl-pythiDC treatment of PDAC cells reduced proliferation, decreased colony formation, and increased G2/M cell cycle arrest. In addition, diethyl-pythiDC increased protein expression of E-cadherin, an epithelial marker, and decreased the expression of N-cadherin and vimentin, the mesenchymal protein markers. Conclusions: Patients with high P4HA1 expression had poor OS. CPTAC data showed higher P4HA1 protein expression in patients with RTK, mTOR and SWI-SNF alterations. Targeting P4HA1 with diethyl-pythiDC reduced proliferation by arresting cells in G2/M phase of the cell cycle and modulated EMT markers. Thus, targeting of P4HA1 can be a viable strategy and may be considered in future PDAC clinical trials. Citation Format: Moh'd Khushman, Farrukh Afaq, Prachi Bajpai, Sameer Al Diffalha, Darryl Outlaw, Grant R. Williams, Rojymon Jacob, Kondal Rao Kyanam Kabir, Ali Ahmed, Peter Shajan, Sooryanarayana Varambally, Upender Manne. The prognostic significance of prolyl 4-hydroxylase subunit alpha 1 and the therapeutic efficacy of diethyl-pythiDC, its small molecule inhibitor, in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1003." @default.
• W4379983886 created "2023-06-10" @default.
• W4379983886 creator A5000425500 @default.
• W4379983886 creator A5015733444 @default.
• W4379983886 creator A5024199124 @default.
• W4379983886 creator A5024813580 @default.
• W4379983886 creator A5038817160 @default.
• W4379983886 creator A5047877371 @default.
• W4379983886 creator A5064186934 @default.
• W4379983886 creator A5069947787 @default.
• W4379983886 creator A5075746614 @default.
• W4379983886 creator A5082199676 @default.
• W4379983886 creator A5087036882 @default.
• W4379983886 creator A5090951584 @default.
• W4379983886 date "2023-04-04" @default.
• W4379983886 modified "2023-09-23" @default.
• W4379983886 title "Abstract 1003: The prognostic significance of prolyl 4-hydroxylase subunit alpha 1 and the therapeutic efficacy of diethyl-pythiDC, its small molecule inhibitor, in pancreatic ductal adenocarcinoma" @default.
• W4379983886 doi "https://doi.org/10.1158/1538-7445.am2023-1003" @default.
• W4379983886 hasPublicationYear "2023" @default.
• W4379983886 type Work @default.
• W4379983886 citedByCount "0" @default.
• W4379983886 crossrefType "journal-article" @default.
• W4379983886 hasAuthorship W4379983886A5000425500 @default.
• W4379983886 hasAuthorship W4379983886A5015733444 @default.
• W4379983886 hasAuthorship W4379983886A5024199124 @default.
• W4379983886 hasAuthorship W4379983886A5024813580 @default.
• W4379983886 hasAuthorship W4379983886A5038817160 @default.
• W4379983886 hasAuthorship W4379983886A5047877371 @default.
• W4379983886 hasAuthorship W4379983886A5064186934 @default.
• W4379983886 hasAuthorship W4379983886A5069947787 @default.
• W4379983886 hasAuthorship W4379983886A5075746614 @default.
• W4379983886 hasAuthorship W4379983886A5082199676 @default.
• W4379983886 hasAuthorship W4379983886A5087036882 @default.
• W4379983886 hasAuthorship W4379983886A5090951584 @default.
• W4379983886 hasConcept C117262875 @default.
• W4379983886 hasConcept C121608353 @default.
• W4379983886 hasConcept C126322002 @default.
• W4379983886 hasConcept C142724271 @default.
• W4379983886 hasConcept C203014093 @default.
• W4379983886 hasConcept C204232928 @default.
• W4379983886 hasConcept C2780210213 @default.
• W4379983886 hasConcept C502942594 @default.
• W4379983886 hasConcept C54355233 @default.
• W4379983886 hasConcept C71924100 @default.
• W4379983886 hasConcept C81885089 @default.
• W4379983886 hasConcept C86803240 @default.
• W4379983886 hasConceptScore W4379983886C117262875 @default.
• W4379983886 hasConceptScore W4379983886C121608353 @default.
• W4379983886 hasConceptScore W4379983886C126322002 @default.
• W4379983886 hasConceptScore W4379983886C142724271 @default.
• W4379983886 hasConceptScore W4379983886C203014093 @default.
• W4379983886 hasConceptScore W4379983886C204232928 @default.
• W4379983886 hasConceptScore W4379983886C2780210213 @default.
• W4379983886 hasConceptScore W4379983886C502942594 @default.
• W4379983886 hasConceptScore W4379983886C54355233 @default.
• W4379983886 hasConceptScore W4379983886C71924100 @default.
• W4379983886 hasConceptScore W4379983886C81885089 @default.
• W4379983886 hasConceptScore W4379983886C86803240 @default.
• W4379983886 hasIssue "7_Supplement" @default.
• W4379983886 hasLocation W43799838861 @default.
• W4379983886 hasOpenAccess W4379983886 @default.
• W4379983886 hasPrimaryLocation W43799838861 @default.
• W4379983886 hasRelatedWork W1570579653 @default.
• W4379983886 hasRelatedWork W1584007117 @default.
• W4379983886 hasRelatedWork W2028359994 @default.
• W4379983886 hasRelatedWork W2043890160 @default.
• W4379983886 hasRelatedWork W2053569846 @default.
• W4379983886 hasRelatedWork W2125923072 @default.
• W4379983886 hasRelatedWork W2764038087 @default.
• W4379983886 hasRelatedWork W2774282247 @default.
• W4379983886 hasRelatedWork W2794847062 @default.
• W4379983886 hasRelatedWork W3013358603 @default.
• W4379983886 hasVolume "83" @default.
• W4379983886 isParatext "false" @default.
• W4379983886 isRetracted "false" @default.
• W4379983886 workType "article" @default.